- Home
- Publications
- Publication Search
- Publication Details
Title
Toll-Like Receptor 9 Agonists in Cancer
Authors
Keywords
-
Journal
OncoTargets and Therapy
Volume Volume 13, Issue -, Pages 10039-10061
Publisher
Informa UK Limited
Online
2020-10-09
DOI
10.2147/ott.s247050
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
- (2020) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization
- (2020) Caitlin D. Lemke-Miltner et al. JOURNAL OF IMMUNOLOGY
- Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
- (2019) Jing Liu et al. OncoImmunology
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development
- (2019) Daniel J Olson et al. Immunotherapy
- Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
- (2019) J E Stein et al. ANNALS OF ONCOLOGY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
- (2019) Alexander M. Menzies et al. JOURNAL OF CLINICAL ONCOLOGY
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- T‐cell receptor and B‐cell receptor repertoire profiling in adaptive immunity
- (2019) Anastasia Minervina et al. TRANSPLANT INTERNATIONAL
- High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
- (2019) Dedong Cao et al. OncoImmunology
- Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
- (2019) Chunwan Lu et al. Journal for ImmunoTherapy of Cancer
- Release from UNC93B1 reinforces the compartmentalized activation of select TLRs
- (2019) Olivia Majer et al. NATURE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
- (2019) Stephanie Dorta-Estremera et al. Journal for ImmunoTherapy of Cancer
- Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response
- (2019) Vered Domankevich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral Immunotherapy—Update 2019
- (2019) Omid Hamid et al. ONCOLOGIST
- The Ubiquitin Code of NODs Signaling Pathways in Health and Disease
- (2019) Rubén Julio Martínez-Torres et al. Frontiers in Immunology
- TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
- (2019) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
- (2019) Hao-Xiang Wu et al. Annals of Translational Medicine
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay
- (2018) Marilena Gallotta et al. CANCER RESEARCH
- Intratumoral CpG-B promotes anti-tumoral neutrophil, cDC, and T cell cooperation without reprograming tolerogenic pDC
- (2018) Marion Humbert et al. CANCER RESEARCH
- The Chaperone UNC93B1 Regulates Toll-like Receptor Stability Independently of Endosomal TLR Transport
- (2018) Karin Pelka et al. IMMUNITY
- Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy
- (2018) Daqing Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The revival of CpG oligonucleotide-based cancer immunotherapies
- (2018) Tomasz Adamus et al. Wspolczesna Onkologia-Contemporary Oncology
- Toll-like receptor 9 activation by CpG oligodeoxynucleotide�7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway
- (2018) Sujuan Yuan et al. Oncology Letters
- Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity
- (2018) Juan Tang et al. Frontiers in Immunology
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study
- (2018) M Thomas et al. ANNALS OF ONCOLOGY
- In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
- (2018) Matthew J. Frank et al. Cancer Discovery
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- NOD1 and NOD2 in inflammation, immunity and disease
- (2018) Tapas Mukherjee et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma—A phase II multicentric, randomised study
- (2017) Renata Ursu et al. EUROPEAN JOURNAL OF CANCER
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer
- (2017) Teuvo L. Tammela et al. JOURNAL OF UROLOGY
- Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications
- (2017) Martina Musella et al. OncoImmunology
- Innate immune signaling and regulation in cancer immunotherapy
- (2016) Leticia Corrales et al. CELL RESEARCH
- Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA
- (2016) Zhikuan Zhang et al. IMMUNITY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses
- (2016) Nicholas J. Hess et al. JOURNAL OF IMMUNOLOGY
- TLR9 stability and signaling are regulated by phosphorylation and cell stress
- (2016) Maroof Hasan et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
- (2015) Emily Chan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
- (2015) Burghardt Wittig et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Space and time: New considerations about the relationship between Toll-like receptors (TLRs) and type I interferons (IFNs)
- (2015) Darren J. Perkins et al. CYTOKINE
- Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
- (2015) Martin R. Weihrauch et al. EUROPEAN JOURNAL OF CANCER
- Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9
- (2015) Umeharu Ohto et al. NATURE
- Toll-like receptor 8 senses degradation products of single-stranded RNA
- (2015) Hiromi Tanji et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
- (2015) M. E. Mikucki et al. Nature Communications
- Toll-like receptor 8 senses degradation products of single-stranded RNA
- (2015) Hiromi Tanji et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Microbiota Modulation of Myeloid Cells in Cancer Therapy
- (2015) R. S. Goldszmid et al. Cancer Immunology Research
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma
- (2015) James Larkin et al. JAMA Oncology
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
- (2014) David A. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2014) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- TLR7 Is Involved in Sequence-Specific Sensing of Single-Stranded RNAs in Human Macrophages
- (2014) M. P. Gantier et al. JOURNAL OF IMMUNOLOGY
- Negative Self-Regulation of TLR9 Signaling by Its N-Terminal Proteolytic Cleavage Product
- (2014) Sungwook Lee et al. JOURNAL OF IMMUNOLOGY
- Determinants of Activity at Human Toll-like Receptors 7 and 8: Quantitative Structure–Activity Relationship (QSAR) of Diverse Heterocyclic Scaffolds
- (2014) Euna Yoo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection
- (2014) S. M. Y. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
- (2013) Chandra P Belani et al. CANCER BIOLOGY & THERAPY
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
- (2013) Jean-Pascal Machiels et al. INVESTIGATIONAL NEW DRUGS
- Identification of TLR10 as a Key Mediator of the Inflammatory Response to Listeria monocytogenes in Intestinal Epithelial Cells and Macrophages
- (2013) T. Regan et al. JOURNAL OF IMMUNOLOGY
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- Heat shock protein gp96 regulates Toll-like receptor 9 proteolytic processing and conformational stability
- (2012) James C. Brooks et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pattern recognition receptors—Molecular orchestrators of inflammation in inflammatory bowel disease
- (2012) David Walsh et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+T-cell responses in melanoma patients
- (2012) Simone M. Goldinger et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
- (2012) Nobutaka Hanagata International Journal of Nanomedicine
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
- (2012) Hélène Salmon et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- Direct Effects of Type I Interferons on Cells of the Immune System
- (2011) S. Hervas-Stubbs et al. CLINICAL CANCER RESEARCH
- Transmembrane Mutations in Toll-like Receptor 9 Bypass the Requirement for Ectodomain Proteolysis and Induce Fatal Inflammation
- (2011) Maria L. Mouchess et al. IMMUNITY
- CD8α+ Dendritic Cells Are the Critical Source of Interleukin-12 that Controls Acute Infection by Toxoplasma gondii Tachyzoites
- (2011) Mona Mashayekhi et al. IMMUNITY
- Immune Signaling by RIG-I-like Receptors
- (2011) Yueh-Ming Loo et al. IMMUNITY
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: A TLR9 Cytoplasmic Tyrosine Motif Is Selectively Required for Proinflammatory Cytokine Production
- (2011) A. Chockalingam et al. JOURNAL OF IMMUNOLOGY
- A Point Mutation in the Amino Terminus of TLR7 Abolishes Signaling without Affecting Ligand Binding
- (2011) Carlo Iavarone et al. JOURNAL OF IMMUNOLOGY
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
- (2011) A. Carpentier et al. NEURO-ONCOLOGY
- The Structural Biology of Toll-like Receptors
- (2011) Istvan Botos et al. STRUCTURE
- Pattern Recognition Receptors and Inflammation
- (2010) Osamu Takeuchi et al. CELL
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immunostimulatory Activity of Unmethylated and Methylated CpG Oligodeoxynucleotide Is Dependent on Their Ability To Colocalize with TLR9 in Late Endosomes
- (2010) S. D. de Jong et al. JOURNAL OF IMMUNOLOGY
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- (2010) Youn H. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b
- (2010) Chaofeng Han et al. NATURE IMMUNOLOGY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells
- (2010) A. L. Blasius et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bifurcation of Toll-Like Receptor 9 Signaling by Adaptor Protein 3
- (2010) M. Sasai et al. SCIENCE
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
- (2009) Jeffrey S. Weber et al. CANCER
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
- (2009) Kazuhiko Yamada et al. CANCER SCIENCE
- Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
- (2009) John A. Thompson et al. Clinical Genitourinary Cancer
- Approaching the Asymptote: 20 Years Later
- (2009) Ruslan Medzhitov IMMUNITY
- Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic Cells
- (2009) Fernando E. Sepulveda et al. IMMUNITY
- Toll-Like Receptor 9-Dependent Activation of Myeloid Dendritic Cells by Deoxynucleic Acids from Candida albicans
- (2009) A. Miyazato et al. INFECTION AND IMMUNITY
- Tumor-reactive CD8+T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: Association with survival
- (2009) Julia Karbach et al. INTERNATIONAL JOURNAL OF CANCER
- IFN- Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity
- (2009) A. G. Sikora et al. JOURNAL OF IMMUNOLOGY
- Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells
- (2009) Giuseppe Mancuso et al. NATURE IMMUNOLOGY
- TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88–independent TLR4 pathway
- (2009) Eva M Palsson-McDermott et al. NATURE IMMUNOLOGY
- TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNA
- (2008) Annapoorani Chockalingam et al. IMMUNOLOGY AND CELL BIOLOGY
- The Crystal Structure of the Human Toll-like Receptor 10 Cytoplasmic Domain Reveals a Putative Signaling Dimer
- (2008) Tomas Nyman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Christian Manegold et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
- Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
- (2008) Julien Fourcade et al. JOURNAL OF IMMUNOTHERAPY
- The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
- (2008) Sarah E. Ewald et al. NATURE
- Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9
- (2008) Boyoun Park et al. NATURE IMMUNOLOGY
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started